Illumina Inc
NASDAQ:ILMN

Watchlist Manager
Illumina Inc Logo
Illumina Inc
NASDAQ:ILMN
Watchlist
Price: 142.95 USD -0.6% Market Closed
Market Cap: 22.7B USD
Have any thoughts about
Illumina Inc?
Write Note

Operating Margin
Illumina Inc

7.8%
Current
1%
Average
2.4%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
7.8%
=
Operating Profit
344m
/
Revenue
4.4B

Operating Margin Across Competitors

Country US
Market Cap 22.7B USD
Operating Margin
8%
Country US
Market Cap 1.3T USD
Operating Margin
14%
Country US
Market Cap 196.2B USD
Operating Margin
17%
Country US
Market Cap 170.9B USD
Operating Margin
21%
Country KR
Market Cap 67.8T KRW
Operating Margin
31%
Country CH
Market Cap 38.5B CHF
Operating Margin
13%
Country US
Market Cap 38.6B USD
Operating Margin
25%
Country US
Market Cap 36.5B USD
Operating Margin
14%
Country US
Market Cap 26.7B USD
Operating Margin
28%
Country US
Market Cap 23.2B USD
Operating Margin
20%
Country US
Market Cap 23B USD
Operating Margin
29%
No Stocks Found

Illumina Inc
Glance View

Market Cap
22.7B USD
Industry
Life Sciences Tools & Services
Economic Moat
None

Illumina Inc. is a pioneering biotechnology company that has revolutionized the field of genomics by developing advanced sequencing technologies that unveil the secrets of the human genome. Founded in 1998 and based in San Diego, California, Illumina has positioned itself at the forefront of genetic research, providing scientists and clinicians with tools that enhance disease detection, treatment options, and personalized medicine. With a commitment to innovation, Illumina’s sequencers have made genetic sequencing faster, cheaper, and more accessible—empowering researchers to explore the genetic underpinnings of health and disease like never before. Their flagship products, such as the NovaSeq and NextSeq series, are instrumental in various applications, from cancer research and reproductive health to infectious disease surveillance. For investors, Illumina represents a unique opportunity in the rapidly expanding biotechnology sector. The company’s robust growth trajectory is underpinned by strategic partnerships with leading research institutions and pharmaceutical companies, fostering a collaborative ecosystem in genomic research and diagnostics. Illumina's strong financial performance is reflected in its consistent revenue growth and expanding market share, making it a formidable player in the global healthcare landscape. As the demand for precision medicine rises and genomic data becomes increasingly integral to modern healthcare, Illumina is poised to capture significant market opportunities. With a focus on innovation, evolving technologies, and a long-term vision for enhancing human health through genomics, Illumina remains a compelling investment proposition in an era where genetic insights are paramount.

ILMN Intrinsic Value
141 USD
Overvaluation 1%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
7.8%
=
Operating Profit
344m
/
Revenue
4.4B
What is the Operating Margin of Illumina Inc?

Based on Illumina Inc's most recent financial statements, the company has Operating Margin of 7.8%.